Michael S. Anderson is CEO at AVADEL PHARMACEUTICALS PLC (AVDL). They have made 12 open-market trades across 2 companies since 2016, most recently 2018-08-10.
CIK 0001144178
11 open-market purchases totalling $516K since 2016, against 1 sale. Across 10 scored buys the stock is down 14.4% at ninety days, and 18.5 points behind the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 36% | 55% | 10% |
| Avg Move | +0.9% | -0.7% | -14.4% |
| Alpha | -0.0% | -2.2% | -18.5% |
| Scored | 11 | 11 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AVDL | SELL | 2018-08-10 | 2018-08-14 | $4.91 | $160K | -12.0% | -8.8% | -30.1% |
| AVDL | BUY | 2018-06-26 | 2018-06-27 | $6.04 | $15K | +1.9% | -2.9% | -32.9% |
| AVDL | BUY | 2018-05-24 | 2018-05-29 | $6.44 | $19K | +17.3% | -7.7% | -32.3% |
| AVDL | BUY | 2017-12-07 | 2017-12-11 | $8.86 | $44K | -11.6% | +2.0% | -18.2% |
| AVDL | BUY | 2017-09-12 | 2017-09-14 | $9.80 | $39K | -0.7% | +5.4% | -10.0% |
| AVDL | BUY | 2017-05-19 | 2017-05-22 | $10.00 | $25K | +5.2% | +11.2% | -10.0% |
| FLML | BUY | 2016-11-21 | 2016-11-22 | $10.64 | $21K | -0.4% | -6.3% | N/A |
| FLML | BUY | 2016-09-02 | 2016-09-07 | $14.12 | $28K | -5.9% | -13.9% | -28.6% |
| FLML | BUY | 2016-08-22 | 2016-08-22 | $14.30 | $72K | -5.9% | -7.5% | -27.0% |
| FLML | BUY | 2016-05-12 | 2016-05-16 | $8.84 | $44K | +11.5% | +2.1% | +38.1% |
| FLML | BUY | 2016-03-18 | 2016-03-21 | $11.04 | $110K | -1.0% | +5.0% | -14.3% |
| FLML | BUY | 2016-03-14 | 2016-03-16 | $9.74 | $97K | -0.6% | +4.9% | -9.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.